Overview

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

Status:
Completed

Trial end date:
2016-02-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess how much of apremilast is found in the blood unchanged when administered as an oral suspension compared to when it is administered as a tablet formulation. The effect of food on apremilast oral suspension will also be evaluated. In addition, information on the safety and tolerability of apremilast will be obtained.

Phase:

Phase 1

Details

Lead Sponsor:

Amgen
Celgene Corporation

Treatments:

Apremilast
Thalidomide